Weekly Spotlight - 21.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

FDA Designates Nipocalimab as Breakthrough Therapy for Sjogren's Disease

The FDA has given nipocalimab a breakthrough therapy designation for treating Sjogren's disease, indicating it shows significant improvement over existing treatments. This designation speeds up the development and review process, potentially bringing this new therapy to patients faster. Nipocalimab targets specific immune cells involved in the disease.

Capstan Therapeutics Shares Promising CAR-T Therapy Data for Autoimmune Diseases

Capstan Therapeutics presented preclinical data on CPTX2309, a CAR-T cell therapy, at the American College of Rheumatology Convergence 2024. The study shows potential for treating autoimmune diseases by targeting specific cells, offering hope for new treatment options. This therapy could potentially reduce inflammation and improve symptoms in conditions like Sjogren's syndrome.

Water Tower Research Gains IRB Approval for Ainos Veldona Study

Water Tower Research has received Institutional Review Board (IRB) approval to conduct a study on Ainos' Veldona, a potential treatment for Sjogren's syndrome. This approval is a significant step forward in evaluating the safety and efficacy of Veldona, which could offer new hope for patients suffering from this autoimmune disorder.

Why Women Are More Prone to Sjogren’s Syndrome

Women are more likely to develop arthritis due to the impact of estrogen on the immune system. Estrogen can both protect and exacerbate joint inflammation, making women more susceptible to autoimmune diseases like rheumatoid arthritis. Hormonal changes, especially during menopause, can also play a role in this increased risk.